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Photodynamic therapy (PDT) based on topical 5-aminolevulinic acid (5-ALA), an endogenous precursor 
of protoporphyrin, is an interesting approach for the treatment of skin cancer. However, 5-ALA is a 
hydrophilic molecule and such a characteristic limits its appropriate cutaneous penetration and retention. 
In this way, more lipophilic molecules, such as esterified 5-ALA derivatives, have been under investigation 
in order to improve the skin penetration of this molecule. Drug formulation can also alter 5-ALA skin 
penetration. Therefore, the aim of this work was to study the influence of ceramide 2 - the main lipid 
of the SC- on the cutaneous delivery of 5-ALA and its ester derivatives in vitro, using Franz diffusion 
cell. The skin permeation of all studied drugs was decreased in the presence of ceramide, representing 
a desirable characteristic in order to avoid the risk of systemic side effects. Nevertheless, the SC and 
[epidermis + dermis] retention after 16 h has also been decreased in the presence of ceramide, as compared 
to control. In conclusion, ceramide was not a good adjuvant, meaning that research of other vehicles 
could be useful to improve cutaneous delivery of 5-ALA.
Uniterms: 5-aminolevulinic acid. Ceramide 2. In vitro/Skin permeation. In vitro/Skin retention. 
Photodynamic therapy.
A Terapia Fotodinâmica (TFD) tópica com um precursor das porfirinas endógenas, o ácido 5-aminolevulínico 
(5-ALA), constitui uma nova modalidade para o tratamento do câncer de pele. Entretanto, o 5-ALA é 
uma molécula hidrofílica, o que limita sua penetração e retenção cutânea apropriadas. Moléculas mais 
lipofílicas, tais como derivados esterificados do 5-ALA, estão sob intensa investigação para melhorar a 
penetração cutânea desta molécula. A formulação que contém o fármaco também pode alterar a penetração 
cutânea do 5-ALA. Desta forma, o objetivo deste trabalho foi estudar a influência da ceramida 2 – o 
principal lipídeo do EC- sobre a penetração cutânea de 5-ALA e seus derivados esterificados usando 
células de difusão de Franz. A permeação de todas as drogas estudadas através da pele foi diminuída na 
presença de ceramida, o que é desejável, evitando riscos de efeitos colaterais sistêmicos. Entretanto, a 
retenção no EC e [epiderme + derme] também foi diminuída na presença da ceramida, após 16 horas, 
comparado ao controle. Concluindo, a ceramida não foi um bom adjuvante, sendo necessária a pesquisa 
de outros veículos para melhorar a liberação cutânea do 5-ALA. 
Unitermos: Ácido 5-aminolevulínico. Ceramida 2. Permeação cutânea/in vitro. Retenção cutânea/in 
vitro. Terapia fotodinâmica.
INTRODUCTION
Exogenous 5-aminolevulinic acid (5-ALA) is beco-
ming widely useful as an inducer of endogenous synthesis 
of protoporphyrin IX (PpIX), a photosensitizer used in 
photodynamic therapy (PDT). Topically ALA-based PDT 
has been successfully used in the treatment of cutaneous 
disease of non-melanoma skin cancer type, mainly in basal 
cell carcinomas and squamous cell carcinomas (Zeitouni et 
al., 2003; Murmur et al., 2004).
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Despite the promising results obtained with 5-ALA, 
a significant limitation for its topical application is the 
poor ability of this molecule to diffuse through biological 
membranes like the stratum corneum (SC), due to its higher 
hydrophilicity. Then, a high dose of 5-ALA must be admi-
nistered, in order to increase PpIX in the tissue at a level that 
is useful for PDT treatment. Hence, improving the uptake of 
5-ALA would be expected, to increase the efficiency of PDT 
(Lopez et al., 2004). 
There are several methods to improve 5-ALA skin 
penetration: (i) changing the drug formulation by adding a 
penetration enhancer (Pierre et al., 2006) or by packaging 
it into a drug delivery system, e.g., liposomes (Pierre et al., 
2001); (ii) applying an electrical current (Lopez et al., 2001); 
(iii) modulating the biosynthetic pathway by the addition of 
iron chelators (Curnow et al., 1998) and (iv) increasing the 
lipophilicity of 5-ALA by its own esterification, for example 
(De Rosa et al., 2003). In topical applications, esters can im-
prove penetration depth as a result of their enhanced lipophi-
licity and also yield a more homogeneous tissue distribution 
(Van Den Akker et al., 2000) leading to shorter application 
times, lower drug doses, lower cost, reduced side-effects 
(e.g. pain), and improved drug stability (Kloeck et al., 1998; 
Gaullier et al., 1997).
It is known that the main skin barrier resides on the stra-
tum corneum (SC) due to the combination of unique properties 
of its components: corneocytes and lipidic barrier (Scheuplein 
et al., 1969; Kessner et al., 2008). The lipids, 2% to 10% of 
the SC, form a hydrophobic layer between cells, avoiding 
the diffusion of water and hydrophilic substances across SC. 
Therefore, intercellular lipids have an important role in the 
maintenance of SC barrier function (Feingold, 2007). Efforts 
to modulate this barrier, in order to increase the penetration of 
drugs to or through the skin have been focused.
SC lipids are composed mainly by free fatty acids, cho-
lesterol, ceramides and cholesteryl sulfates, which represent 
approximately 25 %, 25 %, 40 % and 10 % (w/w) of the SC 
lipids, respectively (Yardley, Summerly, 1981; Long et al., 
1985). In this way, ceramides (CER) constitute the major 
group of lipids in the mammalian SC. 
The CER consist of a long-chain or sphingoid base 
linked to a fatty acid via an amide bond (Figure 1a). CER are 
formed as key intermediates in the biosynthesis of all com-
plex sphingolipids, in which the terminal primary hydroxyl 
group is linked to carbohydrate, phosphate, etc. Unlike the 
sphingoid precursors, they are not soluble in water. 
The CER of the SC can be subdivided in three main 
subgroups, based on the nature of their head group archi-
tectures: sphingosine (S), phytosphingosine (P) or 6-hydro-
xysphingosine (HS) (Figure 1b). Through an amide bond, 
long-chain non-hydroxy (N) or α-hydroxy (A) fatty acids 
with varying acyl chain lengths are chemically linked to the 
sphingosine bases (Wertz, 1992).
The CER consist of, at least, nine different species with 
a wide range of long to very long fatty acid chains (Jeong, Oh, 
2007). The human skin CERs are classified by Arabic numbers, 
changing from 1 to 9 according to their position on thin layer 
chromatography plate (Robson et al., 1994). On the other hand, 
the Roman numbers indicate the commercially available cera-
mide types, so that CER III corresponds to CER 2 while CER 
IV to CER 5 of the human skin (Motta et al., 1994). 
The CER 2 represents the most important fraction 
between all other ceramides that are present in the SC 
(18% w/w) (Wertz et al., 1986). According to Wertz and 
Downing (1983), they protect the epidermal barrier from 
water loss.
The proposal of this work was to study the in vitro 
influence of ceramide 2 on the skin penetration of the hydro-
philic 5-ALA and its lipophilic esters derivatives. Since 
ceramides constitute an abundant component in the SC, their 
exogenous addition could lead to a “reservoir” effect, incre-
asing the retention of lipophilic drugs and facilitating their 
penetration into the skin. In this case, they could improve the 
effect of topical delivery of 5-ALA or its derivatives in 5-ALA 
based-PDT treatment of skin cancers.
MATERIALS AND METHODS
Chemicals
5-ALA hydrochloride was purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Other 5-ALA esters 
FIGURE 1 - (a) General structure of the ceramides. (b) 
Representative molecular structure of SC ceramides according 
to WERTZ (1992). NS: long-chain non-hydroxy fatty acid 
sphingosine, AS: α-hydroxy fatty acid sphingosine, NP: 
long-chain non-hydroxy fatty acid phytosphingosine and AP: 
α-hydroxy fatty acid sphingosine.
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(Table 1) were synthesized as previously described (Kloeck 
et al., 1996), with purity over 95%. Ceramide 2 (CER III) that 
corresponds to synthetic non-hydroxylated fatty acid N-acyl 
sphingosine, prepared from the action of phospholipase C, 
a bovine brain sphingomielin, was purchased from Sigma 
Aldrich Chemie GmbH (Schnelldorf, Germany). All other 
chemicals were of analytical grade. 
Skin
Permeation experiments were performed in full thi-
ckness pig ear skins. Tissue was obtained less than 2 h after 
animal slaughter (Frigorífico Pontal Ltda, Brazil) and used at 
once or stored frozen for a maximum of 30 days before use.
Fluorimetric assay of 5-ALA and its esters
The amounts of 5-ALA were determined after conversion 
of 5-ALA, H-ALA and O-ALA onto its fluorescent derivatives, 
by reaction with acetylacetone and formaldehyde (OISHI et 
al., 1996); the derivative was estimated spectrofluorometri-
cally using a spectrofluorometer (FLUOROLOG 3-Spex, 
Ivon Jobin), with excitation at 378 nm and emission at 464 nm 
(bandwidth 1.5/2.5 nm), by reference to standard curves.
Determination of partition coefficients for 5-ALA 
and its ester derivatives
Partition coefficient octanol/water
The measurements of the 1-octanol/water partition 
coefficients were carried out using the shake-flask method 
according to the OECD guideline 107 (OECD, 1995). The 
5-ALA and its ester derivatives were dissolved in water 
previously saturated with octanol at a concentration of 
60 µg/mL, and mixed with the same volume of octanol 
previously saturated with water. All samples were shaken 
for 30 minutes, centrifuged to separate the two phases, and 
then the amount of 5-ALA and its esters in the aqueous 
phase was quantified. The amount of drugs in octanol phase 
was calculated by subtraction of the measured concentration 
(C) from the initial concentration. The partition coefficients 
(Ko/w) were calculated using the following equation: 
  C octanolKo/w =  –––––––
   C water
Skin/water partition coefficient
This methodology was based on the method propo-
sed previously by Scheuplein et al. (1969). Full-thickness 
skin was excised from the dorsal surface of 4-6 weeks old 
hairless mice HRS/J strain (Jackson Laboratories, Bar 
Harbour, ME). Skin samples (≈ 150 mg) were cut and 
transferred to extraction tubes containing 3.0 mL of 5-ALA 
aqueous solution or its esterified esters, at a concentration 
of 60 µg/mL. The skin and drug aqueous solutions were 
stirred for 6 minutes, filtered by filter paper and then by 
nitrate cellulose membrane of 0.45 µm porosity. The KS/W 
was determined in the aqueous phase by spectrofluori-
metric assay of 5-ALA and its derivatives, according to 
the following equation: KS/W= Cskin/Cwater, where Cskin was 
calculated by the difference between the measured con-
centration and the initial concentration in the water.
In vitro skin permeation studies
Mixtures containing CER III at 2.0% (w/w) and 
5-ALA, H-ALA or O-ALA at 1.0 % (w/w) were obtai-
ned after their dissolution in chloroform: methanol (2:1) 
solvent mixture, followed by drying under nitrogen flow, 
forming a thin film. Next, this film was dispersed in pro-
pylene glycol (PG). Control solutions (without CER) were 
represented by 5-ALA or its derivatives at a 1% concen-
tration, dispersed in PG.
Full thickness porcine ear dorsal skins were ex-
cised and mounted in a modified Franz diffusion cell 
(Microette-Hanson Research, Chatsworth, CA, USA) 
with the dermal side facing downwards into receptor 
medium: 7 mL of isotonic phosphate buffer, pH 5.0 for 
5-ALA and pH 7.2 for its ester derivatives (De Rosa 
et al., 2000). The donor compartment was filled with 
120 µL of the mixtures containing 5-ALA, H-ALA or 
O-ALA at 1% concentration (w/w), and CER III 
(2% w/w) in PG. The total available diffusion area of the 
cell was 1.7 cm2. The system was maintained at 37°C, 
giving a temperature of 32 ºC measured at the SC, and 
the receptor medium was stirred at 300 rpm. At regular 
intervals for up to 16 hours, 1 mL of the receptor phase 
was removed for determination of the total drug content 
permeated through the skin by fluorescence derivatiza-
tion, followed by spectrofluorimetric assay and replaced 
by an equal volume of fresh receptor solution. 
The amount of drug permeated was calculated ac-
cording to the equation: 
TABLE I - 5-ALA and alkyl esters: general structure = 
HCl·NH2−CH2−CO−CH2−CH2CO−OR
1
Drugs Abbreviation R1
5-ALA 5-ALA H
Hexyl-ester H-ALA (CH2)5CH3
Octyl-ester O-ALA (CH2)7CH3
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Q real, t = (C measured, t x Vr + (Va x ∑ 
n-1 Ca), 
where Q= accumulated permeated amount; Q real= real 
value at the time t; C measured, t= concentration measured from 
the sample at time t; V r= volume of the diffusion cell; Va 
= volume of the removed sample and Ca = concentration 
of the removed sample.
Finally, the amount of drugs permeated through the 
skin was divided by the skin area, and these values were 
plotted as a function of the time (µg/cm2).
In vitro skin retention studies
At the end of the above described experiment (after 
16 h), the amount of drug present into the skin was also 
evaluated. For that, the skin was removed from the diffu-
sion cell and pinned to a piece of ParafilmTM with the SC 
face up. That part of the skin, which had been exposed 
to the formulation (1.7cm2), was then tape-stripped 10 
times using Scotch Book Tape n° 845 (3M, St Paul, MN). 
The tape-strips were subsequently immersed in 10 mL 
of methanol in a vial, and shaken for 1 min to extract the 
permeant, before an aliquot of the resulting solution was 
subjected to derivatization and fluorimetric analyses, to 
evaluate the compound in the SC. The remaining skin 
[epidermis without SC + dermis], was cut into small pie-
ces and homogenized with 5 mL of methanol for 1 min, 
sonicated for 30 min and filtered. An aliquot of the filtered 
homogenate was then analyzed by fluorimetric assay, to 
determine the compound quantity in the skin without the 
SC (“viable epidermis”).
RESULTS AND DISCUSSION 
Drugs that are highly hydrophilic or lipophilic 
cannot lead to an optimum passive transport through the 
skin and others biological barriers. Then, the 5-ALA es-
terification aims to increase their lipophilic properties, in 
order to verify if this modification in the 5-ALA molecule 
could really improve skin penetration of the drug. Then, 
partition coefficient studies were realized to evaluate (i) 
the lipophilicity grade, represented by KO/W and (ii) the 
affinity to the full thickness skin (KS/W) of 5-ALA and its 
more lipophilic derivatives. Table II shows partition coe-
fficients studies of 5-ALA, H-ALA and O-ALA. 
As can be seen at Table II, the Ko/w of 5-ALA is low, 
indicating that this molecule is a highly hydrophilic com-
pound. Also, its Ks/w was low, meaning 5-ALA limited 
affinity to the skin. On the contrary, the esterification of 
the drug with hexyl and octyl alcohol increased significan-
tly its lipophilicity. Table II shows that this lipophilicity 
increases with the alkyl chain length of the alcohol used 
in the esterification. In this way, H-ALA is about 3 times 
more lipophilic than 5- ALA, and O-ALA is about 6 times 
more lipophilic than the mother molecule. The esterifica-
tion improves as well the affinity of the drug for the skin, 
as showed by KS/W results. 
Recently, stratum corneum/water partition coeffi-
cients of 5-ALA and several alkyl esters were determined 
by De Rosa et al. (2003) and also showed this effect, that 
is, an increase in the K with the alkyl chain length of the 
ALA ester. 
However, the KSC/W of ALA esters (De Rosa et al., 
2003) is much higher than the KS/W (Table II). These results 
indicated that the affinity of ALA esters for the SC is signi-
ficantly higher than their affinity for the viable epidermis, 
pointing out retention of these esters in the most external 
barrier of the skin, i.e, the SC. They also indicate that the 
esters can penetrate the skin thanks to improvement of 
drug skin affinity. It is well known (Aulton, 2005) that to 
have an efficient topical effect, a drug has to release itself 
from the formulation and enter, by partition and diffusion, 
into the skin. Therefore, the more drug enters the skin, the 
more drug can diffuse to deeper layers of the tissue. In this 
way, the affinity of ALA esters for the SC can lead to an 
improved amount of the drug into skin. It can improve the 
5-ALA bioavailability in the tissue and, possibly, might 
even lead to a more homogeneous distribution of the re-
sulting photosensitizer. 
The SC lipidic lamellae consists mainly of cerami-
des, cholesterol, free fatty acids and cholesteryl sulphate, 
however it is devoid of phospholipids, which are bilayer 
forming components in all other cellular and intracellular 
membranes (Wertz et al, 1986). It was suggested that lipids 
such as ceramides and cholesterol participate of the bilayer 
formation in the SC, providing selectivity in the transcu-
taneous permeation of lipophilic and hydrophilic subs-
tances (Gray, Yardley, 1975). In this way, the similarity 
TABLE II - Octanol/water (KO/W) and skin/water (KS/W) partition 
coefficients (K) of 5-ALA and its n-alkyl esters
Partition 
coefficients
5-ALA H- ALA O-ALA
K O/Wa
0.055 
(± 0.007)
0.1720 
(± 0.035)
0.3205 
(± 0.010)
K S/Wb
0.032 
(± 0.007)
0.2740 
(± 0.135)
0.8265 
(± 0.020)
K sc/w c 0.042 8.169 10.522
a, b Statistic test ONE WAY ANOVA (Tukey’s multiple 
comparisons). c De Rosa et al., 2003
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of composition of the drug delivery system with the main 
SC lipid, the CER III, could lead to a higher interaction 
between formulation and skin, and consequently, a higher 
drug accumulation/retention in the tissue. Thus, in order 
to verify the influence of CER III on cutaneous delivery 
of 5-ALA and its esters, the in vitro skin permeation and 
retention studies were carried out. 
According to Robert (1997), the skin permeability 
to polar solutes can be favored by hydrocarbon based 
vehicles, as CER. In this way, we have expected an im-
proved permeation for 5-ALA dispersed in CER formu-
lation. However, it was not observed in the experiment 
of in vitro skin permeation of our work. Figure 2 shows 
the cumulative amount of 5-ALA, H-ALA and O-ALA 
present in the receptor solution after permeation through 
full-thickness porcine ear skin, after 16 h. It is possible 
to notice that the presence of CER did not increase the 
permeation of 5-ALA and its esters. In the case of 5-ALA, 
it has even decreased significantly the amount of drug in 
the receptor solution.
A reasonable explanation for the results obtained is 
that the propylene glycol, also present in the formulations, 
had changed solubility pattern of the skin (William, Barry, 
2004), increasing the partition coefficient of the drug (to-
gether with CER) to this layer and, therefore, decreasing 
its permeation through the skin. These results, however, 
can be advantageous, once systemic risk effects could be 
avoided by this low permeation and for a topical treatment, 
the drug should be present into the skin and not in the 
circulation (represented by the receptor solution in the in 
vitro experiments). 
To verify the influence of CER in the skin retention 
of 5-ALA and its esters, their presence in the SC and 
“viable epidermis” was also evaluated. As can be seen in 
Figure 3, drugs skin retention was not improved by CER 
presence in the formulation. Moreover, for H-ALA and O-
ALA CER presence has even decreased drug amount in the 
SC (a) and viable epidermis (b), respectively. Therefore, 
CER III was not efficient to improve neither 5-ALA/esters 
derivatives permeation nor retention, when dispersed in a 
propylene glycol solution. 
It has been postulated (Coderch et al., 2003; Bou-
wstra, Ponec, 2006) that formulations containing lipids 
identical to those in skin, in particular, some ceramide 
supplementation could have two divergent actions: (i) 
improve intercellular lamellae disorder or (ii) increase the 
skin lamellar phase, which could difficult the penetration 
of some drugs. These at first sight contradictory effects are 
dependent of the formulation that contains the ceramide. 
It seems that dispersion of CER in propylene glycol leads 
to increase of the skin lamellar phase (Jager et al., 2003). 
Probably, dispersion changes skin pattern, making difficult 
in this case, the drugs diffusion. 
According to Figure 3 (a, b), the H-ALA retention 
is higher than 5-ALA and O-ALA. The same result in SC 
was observed by De Rosa et al. (2003) for these drugs dis-
persed in an O/W emulsion, that is, the H-ALA retention 
in SC was also higher than 5-ALA and O-ALA. 
These authors verified also a small amount of O-
ALA through the skin, and it is probably related to the 
small release of this drug from the formulation (O/A 
emulsion). They have postulated that due to the fact that 
O-ALA is highly lipophilic, its release from this vehicle 
is also difficult, because its interaction with the oil phase 
of the emulsion is also high. The same behavior can be 
observed in Figure 2 (indicating a low skin permeation of 
O-ALA) and Figure 3, where the skin retention of O-ALA 
(SC as well as in epidermis plus dermis) is low, probably 
due to its high affinity to the vehicle, in this case, CER III 
in propylene glycol.
The 5-ALA low retention is much probably related 
to its hydrophilicity, which becomes difficult the drug 
skin penetration. In conclusion, CER III dispersed in a 
propylene glycol vehicle did not improve the skin retention 
and permeation of 5-ALA and its ester derivatives . The 
composition of the formulation where CER III is dispersed 
influences directly its performance. The development of 
appropriate vehicles for 5-ALA and its ester derivatives 
FIGURE 2 - In vitro permeation of 5-ALA, H- ALA and O-ALA 
(μg/cm2) through porcine skin, from PG solution and mixture 
with ceramide (2.0% w/w) in PG, after 16 h of permeation 
experiments. Percentage of 5-ALA and its ester derivatives in 
the formulation: 1.0% (w/w). Values are expressed as S. M. E 
(n=4) for each group. Values are significantly different only 
between 5-ALA control and ceramide + 5-ALA (P < 0.001**). 
Statistical analysis: One- way Anova (Tukey´s multiple 
comparison test).
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is required to improve their skin penetration/retention 
equilibrium.
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